HeartBeat.bio secures €4.5 million in Pre-Series A funding to advance its Cardioid Drug Discovery Platform, targeting significant advancements in cardiac drug discovery.

Target Information

HeartBeat.bio AG is an innovative biotech company focused on developing a unique 3D human tissue-based drug discovery platform known as the Cardioid Drug Discovery Platform, specifically designed for heart disease. This platform enables organoid cultivation, screening, and data analysis, integrating organoid technology with automated hardware solutions and AI-based software. The aim is to facilitate primary drug screening and enable clinical trials-in-a-dish, making drug discovery more efficient and effective.

With the recent closure of a €4.5 million Pre-Series A financing round, HeartBeat.bio plans to use these funds for the commercialization of its Cardioid platform. This financing round, co-led by a syndicate of investors, will support the development of proprietary and collaborative drug discovery programs targeting significant medical needs, such as drug-induced and genetic cardiomyopathies, myocardial infarction, and fibrosis.

Industry Overview

Cardiovascular diseases remain the leading cause of mortality globally. Despite advances in medicine, the development of effective treatments for these conditions has been hampered by high failure rates